US FDA Inspects Aurobindo Pharma Subsidiary; Inspection Concludes with Two Observations
Aurobindo Pharma Ltd.'s wholly owned subsidiary, Auroactive Pharma Private Limited, underwent an inspection by the United States Food and Drug Administration (US FDA). The inspection focused on the manufacturing operations of Active Pharmaceutical Ingredients (API) and Pharmaceutical Formulation Intermediates.The US FDA conducted the inspection at the facility in Andhra Pradesh from June 22, 2026, to June 26, 2026.
According to details provided regarding the regulatory visit, the US FDA concluded the inspection with two observations. The company stated that it will respond to these findings within the stipulated time.
The operational aspects and outcomes of the inspection are summarized below:
| Particulars | Details |
|---|---|
| Authority Name | United States Food and Drug Administration (US FDA), USA |
| Inspection Location & Scope | Auroactive Pharma Private Limited, situated at Sy Nos 231, 285 to 291, Sancham Village, Ranasthalam Mandal, Srikakulam District, Andhra Pradesh. The facility manufactures API and Pharmaceutical Formulation Intermediates. |
| Inspection Period | June 22, 2026, to June 26, 2026 |
| Status of Findings | Two observations were noted by the inspection. |
| Financial Impact | There is no impact on the Company's financials or operations due to the said action. |
The company confirmed its commitment to maintaining the highest quality manufacturing standards and noted that there was no financial or operational impact resulting from the US FDA actions.
AUROPHARMA Stock Price Movement
On Thursday, Aurobindo Pharma Limited shares rallied as the stock settled at ₹1555.20, posting a solid gain of 1.57%. The equity traded robustly across a volume of 2.09 million and neared its annual high, which was registered at ₹1565.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.